Live Chat ×
Skip to main content

Bladder Tumors, Renal Masses, Ovarian Tumors, and Uterine Neoplasms

This item is expired.

Evaluated by: David B. Kaminsky, M.D., FIAC, April 16, 2017 
Original release date: April 16, 2017
Access to this course expires: July 23, 2019, at 11:59 PM Pacific Time
CME / SAM 9.0

Course Description
Especially valuable to surgical pathologists and cytopathologists alike, the latest updates on noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) will help ensure that a subset of indolent thyroid tumors is managed more conservatively and spares patients the anxiety of a cancer diagnosis. The activity will help pathologists and cytopathologists minimize malignant diagnoses on cytology associated with a final diagnosis of NIFTP and identify potential NIFTPs in indeterminate aspirates to promote conservative surgical management.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training.

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Review bladder histology pertinent to diagnosis and stage of bladder cancer 
  • Learn to diagnose papillary and flat urothelial neoplasia, glandular lesions, and variants of urothelial carcinoma 
  • Learn to diagnose bladder tumor invasion and evaluate depth of invasion 
  • Develop a morphology-based differential diagnosis of neoplastic diseases in renal biopsy 
  • Understand the utility and limitation of immunohistochemical markers in the diagnosis of bladder and renal tumors

Continuing Medical Education and Continuing Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 3AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Continuous Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit. Physicians can earn a maximum of 9 SAM credit hours.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships: Steven S. Shen, M.D., Ph.D., Oluwole Fadare, M.D., Charles C. Guo, M.D., Joseph T. Rabban, M.D., MPH

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME and SAM credit, all learners must take a content-based exam and achieve a minimum score of 80%. If learners do not achieve a passing score of 80%, they have the option to retake the exam. After you pass the test and complete the evaluation, your certificate of completion will be available to view and print by clicking here.

Purchasing as a bundle saves 10% over the individual purchase of each course.
Not A Member? Click Here